[go: up one dir, main page]

NO20006604L - Methods and transdermal compositions for pain relief - Google Patents

Methods and transdermal compositions for pain relief

Info

Publication number
NO20006604L
NO20006604L NO20006604A NO20006604A NO20006604L NO 20006604 L NO20006604 L NO 20006604L NO 20006604 A NO20006604 A NO 20006604A NO 20006604 A NO20006604 A NO 20006604A NO 20006604 L NO20006604 L NO 20006604L
Authority
NO
Norway
Prior art keywords
methods
pain relief
transdermal compositions
compositions
amine
Prior art date
Application number
NO20006604A
Other languages
Norwegian (no)
Other versions
NO20006604D0 (en
Inventor
Robert W Murdock
C Donald Williams
Original Assignee
Pharmaceuticals Applic Associa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/106,684 external-priority patent/US6290986B1/en
Application filed by Pharmaceuticals Applic Associa filed Critical Pharmaceuticals Applic Associa
Publication of NO20006604D0 publication Critical patent/NO20006604D0/en
Publication of NO20006604L publication Critical patent/NO20006604L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet fremgangsmåter og sammensetninger for transdermal administrering. Det er beskrevet trekk omfattende fremgangsmåter og sammensetninger for transdermal administrering av en amininneholdende forbindelse med bifasisk oppløselighet og/eller et middel som forsterker aktiviteten av den amininneholdende forbindelsen som har bifasisk oppløselighet, for eksempel et muskelavslappende middel, for å lindre smerte.Methods and compositions for transdermal administration are described. Features are described comprising methods and compositions for transdermally administering an amine-containing compound with biphasic solubility and / or an agent that enhance the activity of the amine-containing compound having biphasic solubility, for example, a muscle relaxant, to relieve pain.

NO20006604A 1998-06-29 2000-12-22 Methods and transdermal compositions for pain relief NO20006604L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/106,684 US6290986B1 (en) 1996-10-24 1998-06-29 Method and composition for transdermal administration of pharmacologic agents
US12290399P 1999-03-05 1999-03-05
PCT/US1999/014653 WO2000000120A1 (en) 1998-06-29 1999-06-29 Methods and transdermal compositions for pain relief

Publications (2)

Publication Number Publication Date
NO20006604D0 NO20006604D0 (en) 2000-12-22
NO20006604L true NO20006604L (en) 2001-02-28

Family

ID=26803907

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006604A NO20006604L (en) 1998-06-29 2000-12-22 Methods and transdermal compositions for pain relief

Country Status (18)

Country Link
EP (1) EP1093348A4 (en)
JP (1) JP2002519310A (en)
KR (1) KR20010078754A (en)
CN (1) CN1331576A (en)
AU (1) AU4841599A (en)
BG (1) BG105175A (en)
BR (1) BR9912508A (en)
CA (1) CA2335837A1 (en)
HR (1) HRP20000905A2 (en)
HU (1) HUP0102728A3 (en)
ID (1) ID28213A (en)
IL (1) IL140420A0 (en)
MX (1) MXPA00012767A (en)
NO (1) NO20006604L (en)
PL (1) PL345216A1 (en)
SK (1) SK20012000A3 (en)
TR (1) TR200003801T2 (en)
WO (1) WO2000000120A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
DE69829048T2 (en) 1997-04-22 2006-02-09 Euro-Celtique S.A. THE USE OF CARBOXYCLIC AND HETEROCYCLIC RESIDUES SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AS SODIUM CHANNEL BLOCKERS
ATE319453T1 (en) 1999-07-01 2006-03-15 Pharmacia & Upjohn Co Llc REBOXETINE FOR THE TREATMENT OF FIBROMYALGIA AND OTHER SOMATOFORM DISORDERS
EP1459749B1 (en) * 1999-07-01 2005-10-05 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating incontinence
AU1261501A (en) * 1999-12-06 2001-06-18 Stanley L. Gore Compositions and methods for intranasal delivery of active agents to the brain
IN191512B (en) * 2000-01-21 2003-12-06 Panacea Biotech
DE10032132A1 (en) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermal therapeutic system containing non-steroidal anti-inflammatory drugs with selective COX-2 inhibition
PT1303265E (en) * 2000-07-20 2007-10-09 Lauras As Use of cox-2 inhibitors as immunostimulants in the treatment of hiv or aids
DE10042412B4 (en) * 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transceiver for bus subscriber of bus system of building system engineering, has two wires, where microcontroller is connected with receiver unit over connection on one hand, which is connected to two wires of bus system
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CA2507522C (en) 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system
JP2005154368A (en) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd Analgesic agent for neuropathic pain containing disopyramide
JP4807721B2 (en) * 2004-01-29 2011-11-02 株式会社 メドレックス Anti-inflammatory analgesic topical
EP2767292B1 (en) 2004-09-17 2016-08-24 Durect Corporation Sustained Local Anesthetic Composition Containing SAIB
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP2007308403A (en) * 2006-05-17 2007-11-29 Kenji Yoshida Skin care preparation
KR100880748B1 (en) * 2006-08-29 2009-02-02 정헌택 Composition for preventing vascular restenosis containing dimethoxycurcumin
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP5826742B2 (en) * 2009-05-07 2015-12-02 ドンコック ファーマシューティカル カンパニー リミテッド Pharmaceutical composition for preventing or treating nerve damage and disease
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
EP3104840B8 (en) * 2014-02-11 2019-07-10 Latitude Pharmaceuticals Inc. Parenteral compositions of celecoxib
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
WO2020084548A1 (en) 2018-10-26 2020-04-30 Viramal Limited Mucoadhesive gel composition
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
KR20220140711A (en) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 Reduced Impurity Sustained Release Drug Delivery Systems and Related Methods
FR3108841B1 (en) * 2020-04-06 2023-11-03 Algotherapeutix TOPICAL PHARMACEUTICAL COMPOSITION IN AQUEOUS GEL FORM COMPRISING AT LEAST AMITRIPTYLINE
EP4277702A1 (en) 2021-01-12 2023-11-22 Durect Corporation Sustained release drug delivery systems and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395420A (en) * 1981-12-09 1983-07-26 Bernstein Joel E Method and composition for treating pruritis
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain

Also Published As

Publication number Publication date
EP1093348A4 (en) 2003-07-16
ID28213A (en) 2001-05-10
NO20006604D0 (en) 2000-12-22
AU4841599A (en) 2000-01-17
KR20010078754A (en) 2001-08-21
HUP0102728A2 (en) 2002-03-28
CA2335837A1 (en) 2000-01-06
JP2002519310A (en) 2002-07-02
TR200003801T2 (en) 2001-06-21
IL140420A0 (en) 2002-02-10
HUP0102728A3 (en) 2002-12-28
CN1331576A (en) 2002-01-16
SK20012000A3 (en) 2001-08-06
WO2000000120A9 (en) 2000-03-30
MXPA00012767A (en) 2002-08-09
PL345216A1 (en) 2001-12-03
EP1093348A1 (en) 2001-04-25
BG105175A (en) 2001-11-30
HRP20000905A2 (en) 2001-08-31
BR9912508A (en) 2001-05-02
WO2000000120A1 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
NO20006604L (en) Methods and transdermal compositions for pain relief
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
WO2002053187A3 (en) Methods and transdermal compositions for pain relief
ATE375341T1 (en) THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OR PREVENTION OF PAIN
NO20061325L (en) Combination of drugs for the treatment of neoplasms
CY1116463T1 (en) Combination therapy for the therapeutic treatment of Protein Deficiency Disorders
DK1476141T3 (en) Manipulation-proof devices for transdermal opioid administration
BR0212078A (en) Method of treating or preventing an amyloid-related disease in a patient, pharmaceutical composition, chemical compound, and use of a compound.
BR0213100A (en) Combinations for the treatment of immunoinflammatory disorders
NO20024646L (en) Combination therapies with vasculature-damaging activity
DK0904067T3 (en) Transdermally administered dextromethorpane as a cough suppressant
EP0754457A4 (en) ANTI-OBESITY AGENT
EA200001010A1 (en) APPLICATION OF DEXMEDETOMIDINE FOR SEDATIVE IMPACT IN THE DEPARTMENT OF INTENSIVE THERAPY
NO20000446D0 (en) Use of physiologically acceptable vanadium compounds, salts and complexes
ATE536178T1 (en) THERAPEUTIC USE OF METHIONINE FOR THE TREATMENT OR PREVENTION OF MUCOSITIS
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
EA200601249A1 (en) PIPERASINS, SUITABLE FOR THE TREATMENT OF PAIN
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
TR200102512T2 (en) The use of saredutan and its pharmaceutically acceptable salts for the preparation of medicinal products useful in the treatment or prevention of all mental disorders, adaptation disorders and various anxiety-depression disorders.
ES2036560T3 (en) A METHOD FOR PREPARING A SYNERGICALLY ACTIVE COMPOSITION FOR THE TREATMENT OF HYPERTENSION.
EA200400348A1 (en) CYPLATINE COMPOSITIONS OF REDUCED TOXICITY AND METHODS OF THEIR APPLICATION
ATE268170T1 (en) USE OF SUMMERIC ACID OR SALTS THEREOF TO TREAT INSULIN RESISTANCE
BR9908452A (en) Fungicidal composition comprising benzoylphenylurea
NO20091111L (en) Use of R (+) - alpha- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidine-methanol for the treatment of sleep disorders
DE60235965D1 (en) COMBINATION OF LEVOSIMENDAN AND A CALCIUM SOURCE FOR THE TREATMENT OF HEART FAILURE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application